Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 17/20 | 0.52 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.47 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | ITK | Q08881 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8739799 | 0.90 | CHEK1 (0.44) | CHEK1ITK | |
| SCHEMBL8739409 | 0.90 | CHEK1 (0.54) | CHEK1ITK | |
| SCHEMBL20055773 | 0.87 | CHEK1 (0.42) | CHEK1MAPK13MAPK12MAPK10MAPK11 | |
| SCHEMBL20055744 | 0.87 | CHEK1 (0.42) | CHEK1ITK | |
| SCHEMBL8738793 | 0.87 | CHEK1 (0.57) | CHEK1ITK | |
| SCHEMBL8739138 | 0.86 | LCK (0.55) | CHEK1ITK | |
| SCHEMBL8739153 | 0.85 | ITK (0.43) | CHEK1ITK | |
| SCHEMBL6125831 | 0.85 | CHEK1 (0.41) | CHEK1MAPK13MAPK12MAPK10MAPK11 | |
| SCHEMBL29470314 | 0.85 | CHEK1 (0.41) | CHEK1MAPK13MAPK12MAPK10MAPK11 | |
| SCHEMBL15673154 | 0.83 | CHEK1 (0.40) | CHEK1ITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180298031-A1 | HETEROCYCLE AMINES AND USES THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2018-10-18 | — | — | US | claimed |
| US-20160347767-A1 | HETEROCYCLE AMINES AND USES THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2016-12-01 | — | — | US | claimed |
| US-20140155379-A1 | HETEROCYCLE AMINES AND USES THEREOF | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-06-05 | — | — | US | claimed |
| US-11773110-B2 | Heterocycle amines and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773110-B2 | Heterocycle amines and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773110-B2 | Heterocycle amines and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2023-10-03 | — | — | US | disclosed |
| US-20220119413-A1 | HETEROCYCLE AMINES AND USES THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2022-04-21 | — | — | US | disclosed |
| US-20220119413-A1 | HETEROCYCLE AMINES AND USES THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2022-04-21 | — | — | US | disclosed |
| US-11186593-B2 | Heterocycle amines and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2021-11-30 | — | — | US | disclosed |
| US-11186593-B2 | Heterocycle amines and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2021-11-30 | — | — | US | disclosed |
| US-20200216468-A1 | HETEROCYCLE AMINES AND USES THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2020-07-09 | — | — | US | disclosed |
| US-9266874-B2 | Heterocycle amines and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2016-02-23 | — | — | US | disclosed |
| US-9266874-B2 | Heterocycle amines and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2016-02-23 | — | — | US | disclosed |
| US-9266874-B2 | Heterocycle amines and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2016-02-23 | — | — | US | disclosed |
| US-20140155379-A1 | HETEROCYCLE AMINES AND USES THEREOF | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140155379-A1 | HETEROCYCLE AMINES AND USES THEREOF | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140155379-A1 | HETEROCYCLE AMINES AND USES THEREOF | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-06-05 | — | — | US | disclosed |
| EP-2730564-A1 | Heterocycle amines and uses thereof | Ligand Pharmaceuticals Inc. (US) | 2014-05-14 | — | — | EP | disclosed |
| EP-2730564-A1 | Heterocycle amines and uses thereof | Ligand Pharmaceuticals Inc. (US) | 2014-05-14 | — | — | EP | disclosed |
| WO-2012068546-A1 | HETEROCYCLE AMINES AND USES THEREOF | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2012-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180298031-A1 | HETEROCYCLE AMINES AND USES THEREOF | HNMT, NQO1, ACHE | CHEK1 395/4885MAPK13 2346/4885MAPK12 3188/4885 |
| US-11773110-B2 | Heterocycle amines and uses thereof | HNMT, NQO1, ACHE | CHEK1 395/4885MAPK13 2346/4885MAPK12 3188/4885 |
| US-20200216468-A1 | HETEROCYCLE AMINES AND USES THEREOF | HNMT, NQO1, ACHE | CHEK1 395/4885MAPK13 2346/4885MAPK12 3188/4885 |
| US-11186593-B2 | Heterocycle amines and uses thereof | HNMT, NQO1, ACHE | CHEK1 395/4885MAPK13 2346/4885MAPK12 3188/4885 |
| US-20160347767-A1 | HETEROCYCLE AMINES AND USES THEREOF | HNMT, NQO1, ACHE | CHEK1 395/4885MAPK13 2346/4885MAPK12 3188/4885 |
| US-20220119413-A1 | HETEROCYCLE AMINES AND USES THEREOF | HNMT, NQO1, ACHE | CHEK1 395/4885MAPK13 2346/4885MAPK12 3188/4885 |
| US-20140155379-A1 | HETEROCYCLE AMINES AND USES THEREOF | HNMT, NQO1, ACHE | CHEK1 395/4885MAPK13 2346/4885MAPK12 3188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.